Bone and mineral disorders in pre-dialysis CKD

International Urology and Nephrology

Volumn 40, Issue 2, 2008, Pages 427-440

  Kovesdy, Csaba P ^a,b   Kalantar Zadeh, Kamyar ^c,d,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Harold Simmons Center for Kidney Disease Research and Epidemiology   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1,25 Dihydroxy cholecalciferol; Chronic kidney disease; FGF 23; Hyperphosphatemia; Mortality; Parathyroid hormone

Indexed keywords

22 OXACALCITRIOL; 25 HYDROXYVITAMIN D; ACTIVATED VITAMIN D; ALFACALCIDOL; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; IRON DERIVATIVE; LANTHANUM CARBONATE; MAGNEBIND; MAGNESIUM DERIVATIVE; NICERITROL; NICOTINAMIDE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; RENVELA; SEVELAMER; SEVELAMER CARBONATE; TUMS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ALUMINUM OVERLOAD; ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEMENTIA; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; HYPERCALCEMIA; HYPERCHLORHYDRIA; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; LOW DRUG DOSE; MEDICAL LITERATURE; METABOLIC ACIDOSIS; METABOLIC DISORDER; MORTALITY; NONHUMAN; OFF LABEL DRUG USE; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PROGNOSIS; RECOMMENDED DRUG DOSE; REFRACTORY ANEMIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

EID: 42549118601     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9346-7     Document Type: Review

References (128)

1. Levin A, Bakris GL, Molitch M et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71:31-38
2. Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218
3. Kalantar-Zadeh K, Kuwae N, Regidor DL et al (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771-780
4. Moe S, Drueke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945-1953
5. Yu AS (2004) Renal transport of calcium, magnesium and phosphate. In: Brenner BM (ed) Brenner & Rector's the kidney, 7th edn. Saunders, Philadelphia
6. Yangawa N, Nakhoul F, Kurokawa K, Lee DB (1994) Physiology of phosphorus metabolism. In: Narins RG (ed) Maxwell and Kleeman's clinical disorders of fluid and electrolyte metabolism, 5th edn. McGraw-Hill, pp 307-371
7. Portale AA, Booth BE, Tsai HC, Morris RC Jr (1982) Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int 21:627-632
8. Eknoyan G, Levin A, Levin N (2003) Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1-201
9. Gupta A, Winer K, Econs MJ et al (2004) FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489-4492
10. Bricker NS (1972) On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med 286:1093-1099
11. Fukagawa M, Kazama JJ (2006) FGF23: Its role in renal bone disease. Pediatr Nephrol 21:1802-1806
12. Gutierrez O, Isakova T, Rhee E et al (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-2215
13. Mucsi I, Hercz G (1998) Control of serum phosphate in patients with renal failure - new approaches. Nephrol Dial Transplant 13:2457-2460
14. K/DOQI (2002) Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1-S266
15. Jono S, McKee MD, Murry CE et al (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-E17
16. Kestenbaum B, Sampson JN, Rudser KD et al (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520-528
17. Menon V, Greene T, Pereira AA et al (2005) Relationship of phosphorus and calcium - phosphorus product with mortality in CKD. Am J Kidney Dis 46:455-463
18. Voormolen N, Noordzij M, Grootendorst DC et al (2007) High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 22:2909-2916
19. Tonelli M, Sacks F, Pfeffer M et al (2005) Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112:2627-2633
20. Chen NX, O'Neill KD, Duan D, Moe SM (2002) Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62:1724-1731
21. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP (2006) Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1:825-831
22. Norris KC, Greene T, Kopple J et al (2006) Baseline predictors of renal disease progression in the African American study of hypertension and kidney disease. J Am Soc Nephrol 17:2928-2936
23. Barsotti G, Morelli E, Giannoni A et al (1983) Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: A controlled trial. Kidney Int Suppl 16:S278-S284
24. Maschio G, Oldrizzi L, Tessitore N et al (1982) Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Kidney Int 22:371-376
25. Ibels LS, Alfrey AC, Haut L, Huffer WE (1978) Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 298:122-126
26. Karlinsky ML, Haut L, Buddington B et al (1980) Preservation of renal function in experimental glomerulonephritis. Kidney Int 17:293-302
27. Lumlertgul D, Burke TJ, Gillum DM et al (1986) Phosphate depletion arrests progression of chronic renal failure independent of protein intake. Kidney Int 29:658-666
28. Kraus ES, Cheng L, Sikorski I, Spector DA (1993) Effect of phosphorus restriction on renal response to oral and intravenous protein loads in rats. Am J Physiol 264:F752-F759
29. Ritz E, Gross ML, Dikow R (2005) Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int Suppl 99:S66-S70
30. Klahr S, Levey AS, Beck GJ et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 330:877-884
31. Sampathkumar K, Selvam M, Sooraj YS et al (2006) Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 38:171-174
32. Llach F, Massry SG (1985) On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61:601-606
33. Salusky IB, Foley J, Nelson P, Goodman WG (1991) Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527-531
34. Thurston H, Swales JD (1971) Aluminium and chronic renal failure. Br Med J 4:490
35. Slatopolsky E, Weerts C, Lopez-Hilker S et al (1986) Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161
36. Braun J, Oldendorf M, Moshage W et al (1996) Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401
37. Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483
38. Guerin AP, London GM, Marchais SJ, Metivier F (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021
39. London GM, Guerin AP, Marchais SJ et al (2003) Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740
40. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K (2008) Battleground: Chronic kidney disorders mineral and bone disease - calcium obsession, vitamin D, and binder confusion. Clin J Am Soc Nephrol 3:168-173
41. Mehrotra R, Budoff M, Christenson P et al (2004) Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int 66:2022-2031
42. Mehrotra R, Budoff M, Hokanson JE et al (2005) Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int 68:1258-1266
43. Qunibi WY, Abouzahr F, Mizani MR et al (2005) Cardiovascular calcification in Hispanic Americans (HA) with chronic kidney disease (CKD) due to type 2 diabetes. Kidney Int 68:271-277
44. Russo D, Palmiero G, De Blasio AP et al (2004) Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 44:1024-1030
45. Tomiyama C, Higa A, Dalboni MA et al (2006) The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 21:2464-2471
46. Russo D, Miranda I, Ruocco C et al (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72(10):1255-1261
47. Shantouf R, Budoff MJ, Ahmadi N et al (2007) Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 28:275-279
48. De Boer IH, Gorodetskaya I, Young B et al (2002) The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 13:2762-2769
49. Fajtova VT, Sayegh MH, Hickey N et al (1995) Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 57:329-335
50. Martinez I, Saracho R, Montenegro J, Llach F (1997) The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496-502
51. Pitts TO, Piraino BH, Mitro R et al (1988) Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67:876-881
52. Reiss E, Canterbury JM, Kanter A (1969) Circulating parathyroid hormone concentration in chronic renal insufficiency. Arch Intern Med 124:417-422
53. St John A, Thomas MB, Davies CP et al (1992) Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 61:422-427
54. Korkor AB (1987) Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316:1573-1577
55. Gogusev J, Duchambon P, Hory B et al (1997) Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51:328-336
56. Kates DM, Sherrard DJ, Andress DL (1997) Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am J Kidney Dis 30:809-813
57. Yamamoto M, Igarashi T, Muramatsu M et al (1989) Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J Clin Invest 83:1053-1056
58. Llach F, Massry SG, Singer FR et al (1975) Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 41:339-345
59. Fuleihan GE, Gundberg CM, Gleason R et al (1994) Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab 79:1642-1647
60. Gupta A, Kallenbach LR, Zasuwa G, Divine GW (2000) Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 11:330-334
61. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2007) Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. Clin J Am Soc Nephrol 2:1024-1029
62. Vincenti F, Arnaud SB, Recker R et al (1984) Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 25:677-682
63. Hutchison AJ, Whitehouse RW, Boulton HF et al (1993) Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44:1071-1077
64. Malluche HH, Ritz E, Lange HP et al (1976) Bone histology in incipient and advanced renal failure. Kidney Int 9:355-362
65. Rix M, Andreassen H, Eskildsen P et al (1999) Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084-1093
66. Sherrard DJ, Hercz G, Pei Y et al (1993) The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 43:436-442
67. Massry SG, Popovtzer MM, Coburn JW et al (1968) Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med 279:697-700
68. Rao DS, Shih MS, Mohini R (1993) Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328:171-175
69. Bogicevic M, Stefanovic V (1988) Relationship between parathyroid hormone and pituitary-testicular axis in patients on maintenance hemodialysis. Exp Clin Endocrinol 92:357-362
70. Tonner DR, Schlechte JA (1993) Neurologic complications of thyroid and parathyroid disease. Med Clin North Am 77:251-263
71. Fellner SK, Lang RM, Neumann A et al (1991) Parathyroid hormone and myocardial performance in dialysis patients. Am J Kidney Dis 18:320-325
72. London GM (2002) Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 1 [17 Suppl]:29-36
73. Tseke P, Grapsa E, Stamatelopoulos K et al (2006) Atherosclerotic risk factors and carotid stiffness in elderly asymptomatic HD patients. Int Urol Nephrol 38:801-809
74. Kovesdy CP, Ahmadzadeh A, Anderson JE, Kalantar-Zadeh K (2008) Outcomes associated with secondary hyperparathyroidism in men with moderate to severe chronic kidney disease. Kidney Int (in press)
75. Avram MM, Mittman N, Myint MM, Fein P (2001) Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38:1351-1357
76. Fouque D, Guebre-Egziabher F (2007) An update on nutrition in chronic kidney disease. Int Urol Nephrol 39:239-246
77. Mafra D, Farage NE, Azevedo DL et al (2007) Impact of serum albumin and body-mass index on survival in hemodialysis patients. Int Urol Nephrol 39:619-624
78. Massry SG, Smogorzewski M (1994) Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219-231
79. Mazzaferro S, Coen G, Bandini S et al (1993) Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. Nephrol Dial Transplant 8:335-340
80. Chiu KC, Chuang LM, Lee NP et al (2000) Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 49:1501-1505
81. Wareham NJ, Byrne CD, Carr C et al (1997) Glucose intolerance is associated with altered calcium homeostasis: A possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 46:1171-1177
82. Gadallah MF, el-Shahawy M, Andrews G et al (2001) Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients. Adv Perit Dial 17:29-36
83. Meytes D, Bogin E, Ma A et al (1981) Effect of parathyroid hormone on erythropoiesis. J Clin Invest 67:1263-1269
84. Neves PL, Trivino J, Casaubon F et al (2002) Elderly patients on chronic hemodialysis: Effect of the secondary hyperparathyroidism on the hemoglobin level. Int Urol Nephrol 34:147-149
85. Neves PL, Trivino J, Casaubon F et al (2006) Elderly patients on chronic hemodialysis with hyperparathyroidism: Increase of hemoglobin level after intravenous calcitriol. Int Urol Nephrol 38:175-177
86. Massry SG, Alexiewicz JM, Gaciong Z, Klinger M (1991) Secondary hyperparathyroidism and the immune system in chronic renal failure. Semin Nephrol 11:186-201
87. Baczynski R, Massry SG, Kohan R et al (1985) Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 27:718-725
88. Amann K, Ritz E (1997) Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 4:212-224
89. Kosch M, Hausberg M, Vormbrock K et al (2000) Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 47:813-818
90. Amann K, Tornig J, Flechtenmacher C et al (1995) Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: Evidence for a permissive action of PTH. Nephrol Dial Transplant 10:2043-2048
91. Kamycheva E, Sundsfjord J, Jorde R (2004) Serum parathyroid hormone levels predict coronary heart disease: The Tromsø study. Eur J Cardiovasc Prev Rehabil 11:69-74
92. Ichikawa I, Humes HD, Dousa TP, Brenner BM (1978) Influence of parathyroid hormone on glomerular ultrafiltration in the rat. Am J Physiol 234:F393-F401
93. Marchand GR (1985) Effect of parathyroid hormone on the determinants of glomerular filtration in dogs. Am J Physiol 248:F482-F486
94. Lee K, Brown D, Urena P et al (1996) Localization of parathyroid hormone/ parathyroid hormone-related peptide receptor mRNA in kidney. Am J Physiol 270:F186-F191
95. Endlich N, Nobiling R, Kriz W, Endlich K (2001) Expression and signaling of parathyroid hormone-related protein in cultured podocytes. Exp Nephrol 9:436-443
96. Shigematsu T, Caverzasio J, Bonjour JP (1993) Parathyroid removal prevents the progression of chronic renal failure induced by high protein diet. Kidney Int 44:173-181
97. Baker LR, Abrams L, Roe CJ et al (1989) 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661-669
98. Bianchi ML, Colantonio G, Campanini F et al (1994) Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9:1595-1599
99. Goodman WG, Coburn JW (1992) The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 43:227-237
100. Martin KJ, Gonzalez EA, Gellens M et al (1998) 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427-1432
101. Kazama JJ, Maruyama H, Narita I, Gejyo F (2005) Maxacalcitol is a possible less phosphatemic vitamin D analog. Ther Apher Dial 9:352-354
102. Goodman WG, Hladik GA, Turner SA et al (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024
103. Taskapan H, Wei M, Oreopoulos DG (2006) 25(OH) vitamin D3 in patients with chronic kidney disease and those on dialysis: Rediscovering its importance. Int Urol Nephrol 38:323-329
104. Saab G, Young DO, Gincherman Y et al (2007) Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105:c132-c138
105. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ (2006) 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70:654-659
106. Teng M, Wolf M, Ofsthun MN et al (2005) Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16:1115-1125
107. Tentori F, Hunt WC, Stidley CA et al (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858-1865
108. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008) Association of treatment with activated vitamin D and mortality in chronic kidney disease. Arch Intern Med 168:397-403
109. Shoben AB, Rudser KD, de Boer IH et al (2007) Oral calcitriol use and mortality in non-dialyzed patients with chronic kidney disease [abstract]. J Am Soc Nephrol 18:98A
110. Bellows CG, Reimers SM, Heersche JN (1999) Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res 297:249-259
111. Drissi H, Pouliot A, Koolloos C et al (2002) 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 274:323-333
112. Virdi AS, Cook LJ, Oreffo RO, Triffitt JT (1998) Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol (Noisy-le-grand) 44:1237-1246
113. Fraser JD, Otawara Y, Price PA (1988) 1,25-Dihydroxyvitamin D3 stimulates the synthesis of matrix gamma-carboxyglutamic acid protein by osteosarcoma cells. Mutually exclusive expression of vitamin K-dependent bone proteins by clonal osteoblastic cell lines. J Biol Chem 263:911-916
114. Panichi V, De Pietro S, Andreini B et al (1998) Calcitriol modulates in vivo and in vitro cytokine production: A role for intracellular calcium. Kidney Int 54:1463-1469
115. Staeva-Vieira TP, Freedman LP (2002) 1,25-dihydroxyvitamin D3 inhibits IFN-gamma and IL-4 levels during in vitro polarization of primary murine CD4 + T cells. J Immunol 168:1181-1189
116. Barrat FJ, Cua DJ, Boonstra A et al (2002) In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195:603-616
117. Boonstra A, Barrat FJ, Crain C et al (2001) 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167:4974-4980
118. Aihara K, Azuma H, Akaike M et al (2004) Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 279:35798-35802
119. Wolf M, Shah A, Gutierrez O et al (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004-1013
120. Watson KE, Abrolat ML, Malone LL et al (1997) Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96:1755-1760
121. Bertoli M, Luisetto G, Ruffatti A et al (1990) Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 33:98-102
122. Coen G, Mazzaferro S, Manni M et al (1994) No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. Nephrol Dial Transplant 9:1520
123. Agarwal R, Acharya M, Tian J et al (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823-2828
124. Nagakura K, Abe E, Suda T et al (1986) Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int 29:834-840
125. Penna G, Adorini L (2000) 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405-2411
126. Gysemans C, Van EE, Overbergh L et al (2002) Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha,25-dihydroxyvitamin-D3. Clin Exp Immunol 128:213-220
127. Li YC, Kong J, Wei M et al (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238
128. Charytan C, Coburn JW, Chonchol M et al (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46:58-67